Profile
Sector:
HealthcareIndustry:
Drug Manufacturers - GeneralCountry:
United StatesIPO:
17 September 1991Website:
http://www.biogen.comNext earnings report:
25 July 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 22 min agoDividend
Analysts recommendations
Institutional Ownership
BIIB Latest News
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=88841&wire=1 or contact Joseph E. Levi, Esq.
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=88833&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. ("Biogen" or "the Company") (NASDAQ: BIIB ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before July 22, 2024.
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=88813&wire=1 or contact Joseph E. Levi, Esq.
SAN DIEGO, July 02, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of persons and entities that purchased or otherwise acquired Biogen Inc. (NASDAQ: BIIB) securities between February 3, 2022 and February 13, 2024. Biogen is a global biopharmaceutical company that discovers, develops, and delivers therapies for people living with serious and complex diseases worldwide.
Eli Lilly won FDA approval for its Alzheimer's treatment, donanemab, on Tuesday. But Eli Lilly stock remained in the red.
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=88771&wire=1 or contact Joseph E. Levi, Esq.
LOS ANGELES, July 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 3, 2022 and February 13, 2024, inclusive (the “Class Period”), are encouraged to contact the firm before July 22, 2024.
NEW YORK, NY / ACCESSWIRE / July 2, 2024 / If you suffered a loss on your Biogen Inc. (NASDAQ:BIIB) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/biogen-lawsuit-submission-form?prid=88735&wire=1 or contact Joseph E. Levi, Esq.
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases (IMDs).
What type of business is Biogen?
Biogen Inc. is a global biopharmaceutical company specializing in the discovery, development, and sale of innovative drugs for the treatment of serious neurological, neuroimmune, and neurodegenerative diseases: multiple sclerosis, Alzheimer's disease, dementia, movement disorders (including Parkinson's disease), neuromuscular disorders (including spinal muscular atrophy, amyotrophic lateral sclerosis). The company's activities are also focused on discovering and developing innovative treatments for hematological diseases, neurocognitive disorders, pain, ophthalmology, and rare genetic diseases. Biogen Inc. also manufactures and sells biological analogues of advanced biological drugs. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
What sector is Biogen in?
Biogen is in the Healthcare sector
What industry is Biogen in?
Biogen is in the Drug Manufacturers - General industry
What country is Biogen from?
Biogen is headquartered in United States
When did Biogen go public?
Biogen initial public offering (IPO) was on 17 September 1991
What is Biogen website?
https://www.biogen.com
Is Biogen in the S&P 500?
Yes, Biogen is included in the S&P 500 index
Is Biogen in the NASDAQ 100?
Yes, Biogen is included in the NASDAQ 100 index
Is Biogen in the Dow Jones?
No, Biogen is not included in the Dow Jones index
When does Biogen report earnings?
The next expected earnings date for Biogen is 25 July 2024